|
Press Releases |
|
|
|
Thursday, June 29, 2023 |
|
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun |
NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. more info >> |
|
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun |
NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. more info >> |
|
Wednesday, September 16, 2020 |
|
NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19 |
NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has nominated a clinical drug candidate for the treatment of COVID-19, thus further advancing its COVID-19 program closer to human clinical trials. more info >> |
|
Wednesday, May 20, 2020 |
|
Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus |
NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases. more info >> |
|
Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus |
NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases. more info >> |
|
Tuesday, March 17, 2020 |
|
NanoViricides公司冠状病毒药物开发更新 |
NanoViricides公司(美国纽约证券交易所交易代码 NNVC)(公司)是基于新型纳米药学平台(公司)开发高效抗病毒治疗方法的领先公司,目前正在为造成COVID-19的当前新型冠状病毒SARS-CoV-2进行药物开发,现提供其工作相关更新。 more info >> |
|
NanoViricides公司冠狀病毒藥物開發更新 |
NanoViricides公司(美國紐約證券交易所交易代碼NNVC)(公司)是基於新型納米藥學平台(公司)開發高效抗病毒治療方法的領先公司,目前正在為造成COVID-19的當前新型冠狀病毒SARS-CoV-2進行藥物開發,現提供其工作相關更新。 more info >> |
|
NanoViricides社、新型コロナウイルス治療薬開発に関する最新情報を発表 |
新たなナノ医療プラットフォームを基盤に非常に効果的な抗ウイルス療法の開発でリードするNanoViricides社(NYSE American: NNVC) (以下「当社」)は、COVID-19を引き起こす現在の新型コロナウイルス(SARS-CoV-2)の治療薬開発に向けた取り組みについて最新情報を提供しています。 more info >> |
|
Monday, March 16, 2020 |
|
Coronavirus Drug Development Update from NanoViricides, Inc. |
NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19. more info >> |
|
Coronavirus Drug Development Update from NanoViricides, Inc. |
NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Netjoy records new high gross billing hitting RMB8.137 billion in 2023
Mar 29, 2024 12:27 HKT/SGT
|
|
|
中国生物制药(1177.HK)公布2023全年业绩
Mar 29, 2024 12:15 HKT/SGT
|
|
|
中國生物製藥(1177.HK)公布2023全年業績
Mar 29, 2024 12:09 HKT/SGT
|
|
|
Sino Biopharm (1177.HK) Announces 2023 Annual Results
Mar 29, 2024 11:45 HKT/SGT
|
|
|
Wintermar Offshore (WINS:JK) Reports FY2023 Results
Mar 29, 2024 10:15 HKT/SGT
|
|
|
TANAKA Memorial Foundation Announces Recipients of Precious Metals Research Grants
Mar 29, 2024 11:00 JST
|
|
|
Fujitsu Selected as CDP Supplier Engagement Leader
Mar 29, 2024 10:28 JST
|
|
|
Mazda Production and Sales Results for February 2024
Mar 29, 2024 10:00 JST
|
|
|
Finerca Celebrates Milestone of 10,000 Clients with Launch of Exclusive Master Course in CFD Trading
Mar 29, 2024 06:48: JST
|
|
|
Avance Clinical은 세계 백신 대회에서 최신 백신 임상시험 뉴스를 공유합니다. 이 중에는 HIV-1 연구도 포함됩니다
Mar 29, 2024 06:42 HKT/SGT
|
|
|
Avance Clinical將在世界疫苗大會上分享最新的疫苗臨床試驗新聞,包括HIV-1研究
Mar 29, 2024 06:33 HKT/SGT
|
|
|
Avance Clinical将在世界疫苗大会上分享最新的疫苗临床试验新闻,包括HIV-1研究
Mar 29, 2024 06:22 HKT/SGT
|
|
|
703-Carat L'Heure Bleu Tanzanite Carving Sets New GUINNESS WORLD RECORDS(TM) Title as World's Largest Cut Tanzanite
Mar 29, 2024 06:00 HKT/SGT
|
|
|
Finerca Celebrates Milestone of 10,000 Clients with Launch of Exclusive Master Course in CFD Trading
Mar 29, 2024 05:36 HKT/SGT
|
|
|
Atlas Lithium Secures US$ 30,000,000 Strategic Investment and Offtake Agreement from Mitsui
Mar 28, 2024 19:09 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|